120017
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
针刀联合塞来昔布和正骨伸筋胶囊治疗腰椎间盘突出症：一项倾向评分匹配回顾性队列研究
Received 26 January 2026
Accepted for publication 26 March 2026
Published 21 April 2026 Volume 2026:19 594368
DOI https://doi.org/10.2147/JPR.S594368
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Houman Danesh
Xiuchen Sun,1 Shuaimei Zhang,2 Shuojun Liu3
1Pain Clinic, Shandong Wendeng Orthopedics Hospital, Weihai, Shandong, People’s Republic of China; 2Department of Emergency, Shandong Wendeng Orthopedics Hospital, Weihai, Shandong, People’s Republic of China; 3Department of Science and Education, Shandong Wendeng Orthopedics Hospital, Weihai, Shandong, People’s Republic of China
Correspondence: Shuojun Liu, Email 13869012208@163.com
Background: Lumbar disc herniation (LDH) is a leading cause of chronic low back pain, affecting approximately 1– 3% of the general population annually with substantial socioeconomic burden. Acupotomy, a minimally invasive Traditional Chinese Medicine (TCM) technique, has demonstrated promise in musculoskeletal disorders, yet large-scale evidence evaluating its combination with pharmacotherapy remains limited. This study evaluated the efficacy and safety of acupotomy combined with celecoxib and Zhenggu Shenjin capsules versus pharmacotherapy alone in patients with LDH.
Methods: This retrospective cohort study analyzed electronic medical records of 800 LDH patients treated at Shandong Wendeng Orthopedic Hospital between February 2023 and October 2024. Using 1:1 propensity score matching (PSM), patients were allocated to the experimental group (acupotomy plus celecoxib 200 mg twice daily and Zhenggu Shenjin capsules 0.99 g three times daily for 4 weeks, n=400) or the control group (celecoxib 200 mg twice daily and Zhenggu Shenjin capsules 0.99 g three times daily without acupotomy, n=400). Primary outcomes included Visual Analog Scale (VAS) and Oswestry Disability Index (ODI) changes at 3 months post-treatment. Secondary outcomes encompassed overall efficacy rates and adverse events (AEs).
Results: Following PSM, baseline characteristics were well-balanced (all standardized mean differences < 0.10). The experimental group demonstrated significantly greater VAS reduction (4.12± 1.28 vs 2.68± 1.15, P< 0.001) and ODI improvement (22.85± 8.47% vs 13.76± 7.21%, P< 0.001) compared to controls. Overall efficacy rate was significantly higher (78.50% vs 58.75%, P< 0.001), while adverse event incidence was lower (4.25% vs 11.50%, P< 0.001). Subgroup analyses showed consistent benefits across all strata, with younger patients (< 50 years; P-interaction=0.042) and those with shorter symptom duration (< 6 months; P-interaction=0.008) deriving greatest benefit.
Conclusion: Acupotomy combined with celecoxib and Zhenggu Shenjin capsules demonstrated superior pain relief, functional improvement, and safety profile compared to pharmacotherapy alone for LDH treatment. These findings support the integration of this regimen into clinical guidelines for non-surgical LDH management and warrant prospective validation through multicenter randomized controlled trials.
Keywords: acupotomy, lumbar disc herniation, traditional Chinese medicine, celecoxib, zhenggu shenjin capsules, propensity score matching, retrospective cohort study
1Pain Clinic, Shandong Wendeng Orthopedics Hospital, Weihai, Shandong, People’s Republic of China; 2Department of Emergency, Shandong Wendeng Orthopedics Hospital, Weihai, Shandong, People’s Republic of China; 3Department of Science and Education, Shandong Wendeng Orthopedics Hospital, Weihai, Shandong, People’s Republic of China
Correspondence: Shuojun Liu, Email 13869012208@163.com
Background: Lumbar disc herniation (LDH) is a leading cause of chronic low back pain, affecting approximately 1– 3% of the general population annually with substantial socioeconomic burden. Acupotomy, a minimally invasive Traditional Chinese Medicine (TCM) technique, has demonstrated promise in musculoskeletal disorders, yet large-scale evidence evaluating its combination with pharmacotherapy remains limited. This study evaluated the efficacy and safety of acupotomy combined with celecoxib and Zhenggu Shenjin capsules versus pharmacotherapy alone in patients with LDH.
Methods: This retrospective cohort study analyzed electronic medical records of 800 LDH patients treated at Shandong Wendeng Orthopedic Hospital between February 2023 and October 2024. Using 1:1 propensity score matching (PSM), patients were allocated to the experimental group (acupotomy plus celecoxib 200 mg twice daily and Zhenggu Shenjin capsules 0.99 g three times daily for 4 weeks, n=400) or the control group (celecoxib 200 mg twice daily and Zhenggu Shenjin capsules 0.99 g three times daily without acupotomy, n=400). Primary outcomes included Visual Analog Scale (VAS) and Oswestry Disability Index (ODI) changes at 3 months post-treatment. Secondary outcomes encompassed overall efficacy rates and adverse events (AEs).
Results: Following PSM, baseline characteristics were well-balanced (all standardized mean differences < 0.10). The experimental group demonstrated significantly greater VAS reduction (4.12± 1.28 vs 2.68± 1.15, P< 0.001) and ODI improvement (22.85± 8.47% vs 13.76± 7.21%, P< 0.001) compared to controls. Overall efficacy rate was significantly higher (78.50% vs 58.75%, P< 0.001), while adverse event incidence was lower (4.25% vs 11.50%, P< 0.001). Subgroup analyses showed consistent benefits across all strata, with younger patients (< 50 years; P-interaction=0.042) and those with shorter symptom duration (< 6 months; P-interaction=0.008) deriving greatest benefit.
Conclusion: Acupotomy combined with celecoxib and Zhenggu Shenjin capsules demonstrated superior pain relief, functional improvement, and safety profile compared to pharmacotherapy alone for LDH treatment. These findings support the integration of this regimen into clinical guidelines for non-surgical LDH management and warrant prospective validation through multicenter randomized controlled trials.
Keywords: acupotomy, lumbar disc herniation, traditional Chinese medicine, celecoxib, zhenggu shenjin capsules, propensity score matching, retrospective cohort study